In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

Sign up to save your podcasts

S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

S3 Ep31: Talking KRAS-Targeted Therapy in NSCLC With Dr. Levy

More shows like OncLive® On Air

Left, Right & Center

The Ben Shapiro Show

NEJM This Week

Nature Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Audio Journal of Oncology Podcast

OncoPharm

ASCO Guidelines

The Uromigos

Simple English News Daily

Oncology Today with Dr Neil Love

People I (Mostly) Admire

Oncology Brothers: Practice-Changing Cancer Discussions

English Learning Podcast